Immune targeting of PD-1hi expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques  by Vargas-Inchaustegui, Diego A. et al.
Immune targeting of PD-1hi expressing cells during and after
antiretroviral therapy in SIV-infected rhesus macaques
Diego A. Vargas-Inchaustegui a, Peng Xiao a,1, Alison E. Hogg a,2, Thorsten Demberg a,
Katherine McKinnon a, David Venzon b, Egidio Brocca-Cofano a,3, Janet DiPasquale a,
Eun M. Lee c, Lauren Hudacik c, Ranajit Pal c, Yongjun Sui a, Jay A. Berzofsky a, Linda Liu d,
Solomon Langermann d, Marjorie Robert-Guroff a,n
a Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
b Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
c Advanced Bioscience Laboratories Inc., Rockville, MD 20850, USA
d Amplimmune Inc., Gaithersburg, MD 20878, USA
a r t i c l e i n f o
Article history:
Received 28 June 2013
Returned to author for revisions
5 August 2013
Accepted 13 September 2013
Available online 9 October 2013
Keywords:
PD-1
Treg
ART
Immunomodulation
Viremia
a b s t r a c t
High-level T cell expression of PD-1 during SIV infection is correlated with impaired proliferation and
function. We evaluated the phenotype and distribution of T cells and Tregs during antiretroviral therapy
plus PD-1 modulation (using a B7-DC-Ig fusion protein) and post-ART. Chronically SIV-infected rhesus
macaques received: 11 weeks of ART (Group A); 11 weeks of ART plus B7-DC-Ig (Group B); 11 weeks of
ART plus B7-DC-Ig, then 12 weeks of B7-DC-Ig alone (Group C). Continuous B7-DC-Ig treatment (Group C)
decreased rebound viremia post-ART compared to pre-ART levels, associated with decreased PD-1hi
expressing T cells and Tregs in PBMCs, and PD-1hi Tregs in lymph nodes. It transiently decreased expression
of Ki67 and α4β7 in PBMC CD4þ and CD8þ Tregs for up to 8 weeks post-ART and maintained Ag-speciﬁc
T-cell responses at low levels. Continued immune modulation targeting PD-1hi cells during and post-ART
helps maintain lower viremia, keeps a favorable T cell/Treg repertoire and modulates antigen-speciﬁc
responses.
Published by Elsevier Inc.
Introduction
T cell exhaustion, which leads to progressive loss of T cell
antigen-speciﬁc function, is one of the major hurdles in the
efﬁcient treatment of chronic viral infections (Day et al., 2006;
Porichis and Kaufmann, 2012; Wherry, 2011) and malignant
neoplastic diseases (Kim and Ahmed, 2010; Norde et al., 2012).
Programmed death-1 (PD-1), an inhibitory surface co-receptor, is a
member of the CD28/B7 family that is expressed on T cells, B cells
and myeloid-derived cells (Riley, 2009; Ishida et al., 1992). There
are two known ligands of PD-1: PD-L1 (B7-H1) and PD-L2 (B7-DC),
which are expressed on the surface of a variety of hematopoietic
(T cells, B cells, dendritic cells and macrophages) and non-
hematopoietic cells (endothelial cells and ﬁbroblasts) (Keir et al.,
2006; Singh et al., 2011; Rodriguez-Garcia et al., 2011; Messal
et al., 2011; Francisco et al., 2010). Upon ligand–receptor interac-
tion, PD-1 dampens TCR signaling, thus reducing cell proliferation
and cytokine production, while favoring cell anergy and apoptosis
(Wherry, 2011; Riley, 2009). PD-1 over-expression has been
associated with T cell and Treg dysfunction in a variety of chronic
viral infections such as HCV, HBV, HIV/SIV and LCMV (Day et al.,
2006; Yao et al., 2007; Kasprowicz et al., 2008; Velu et al., 2009;
Petrovas et al., 2007; Moorman et al., 2011; Jin et al., 2010;
Franceschini et al., 2009; Shen et al., 2011). Particularly in the
case of HIV infection, increased PD-1 expression on antigen-
speciﬁc CD4þ and CD8þ T cells has been associated with T cell
exhaustion and disease progression (Day et al., 2006), and has
been identiﬁed as a unique marker for failing immune reconstitu-
tion in HIV patients undergoing antiretroviral therapy (ART)
(Grabmeier-Pﬁstershammer et al., 2011). Similarly, PD-1 expres-
sion levels have also been used as a reliable indicator of low-level
HIV-1 and SIV replication (Salisch et al., 2010). Although ART has
decreased the morbidity and mortality associated with HIV infec-
tion globally (Moore et al., 2012), complete eradication of the viral
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reservoir (Margolis, 2011; Pace et al., 2011), as well as reduction of
ART-associated side-effects, remain priorities in the development
of new treatment strategies against HIV infection (Calza, 2012).
Similarly, the identiﬁcation of immunomodulatory therapies that
might assist in viral reservoir eradication and improve Ag-speciﬁc
immune responses is of great therapeutic interest.
Given that PD-1 over-expression has been extensively asso-
ciated with T cell exhaustion, recent efforts have been directed
towards improving T cell functionality during chronic viral infec-
tion and neoplastic malignancies by in vivo PD-1 blockade
(Porichis and Kaufmann, 2012; Nakamoto et al., 2008; Sakthivel
et al., 2012; Kaufmann and Walker, 2009; Curiel et al., 2003;
Mkrtichyan et al., 2011). In the present study, we chose to target
PD-1 by using B7-DC-Ig (Amplimmune, Inc.), a fusion protein
consisting of the extracellular domain (ECD) of human B7-DC
and the hinge and Fc domain of human IgG1. Murine B7-DC-Ig
(ECD of murine B7-DC fused with the hinge and Fc domain of
murine IgG2a) in combination with cyclophosphamide has been
previously shown to enhance vaccine-mediated Ag-speciﬁc immune
responses in a murine TC-1 tumor model. Furthermore, the
enhancement of Ag-speciﬁc immune responses was due to a
decrease in the number of tumor-inﬁltrated Tregs and to an overall
decrease in PDhi CD8þ T cells. Importantly, murine B7-DC-Ig does
not block PD-1/PD-L1 interaction or PD-1 detection by ﬂow cyto-
metry, and acts only on cells expressing high amounts of PD-1 on
the cell surface (Mkrtichyan et al., 2012). In order to test the
potential PD-1 immunomodulatory properties of B7-DC-Ig in the
context of SIV infection, we used chronically SIVmac251-infected
rhesus macaques and treated them with a triple cocktail of
antiretroviral drugs with or without supplemental PD-1 immuno-
modulation (through the use of B7-DC-Ig). Concurrently, we also
evaluated the impact of continuous PD-1 immunomodulation as a
single therapeutic agent, by continuing B7-DC-Ig treatment for up to
12 weeks post-ART release. Because of the well-documented effects
of ART on Tregs and T cells, throughout the study we evaluated the
phenotype and distribution of both cell types in different tissue
compartments and T-cell functionality. Our results suggest that
prolonged in vivo targeting of PD-1 with B7-DC-Ig during and after
ART favors lower systemic viral loads and helps maintain a favorable
Treg and T cell repertoire.
Results
SIV-associated increased levels of PD-1 expression in T cells and Tregs
In order to evaluate the effect of in vivo targeting of the PD-1
pathway during and after ART, we ﬁrst analyzed the distribution of
PD-1 expressing T cells and Tregs (Fig. 1A) in peripheral blood
mononuclear cells (PBMCs) and lymph nodes (LN). As previously
reported (Salisch et al., 2010), compared to naïve macaques, the
frequency of total PD-1 expression in PBMCs of SIV-infected
macaques was increased in both CD4þ and CD8þ T cells, without
a signiﬁcant increase in CD4þ or CD8þ Tregs (Fig. 1B). Interest-
ingly, when evaluating LN of SIV-infected macaques, a signiﬁcant
increase in total PD-1 expression was observed in both T cells
and Tregs when compared to naïve animals (Fig. 1C). Similar to
previous reports (Salisch et al., 2010), we conﬁrmed that PD-1 is
differentially expressed within CD4þ and CD8þ T cell subsets in
naïve animals, and signiﬁcantly increased in CD4þ and CD8þ
central memory T cells of SIV-infected macaques (Fig. 1D). Given
that PD-1 expression in T cells and Tregs follows a bimodal
distribution (Fig. 2A), and that PD-1hi cells represent an anergic
population of T cells that can be directly targeted by murine
Fig. 1. Increased expression of PD-1 is observed in central memory T cells as well as in CD4þ and CD8þ Tregs in SIV-infected rhesus macaques. Freshly isolated PBMC and LN
single-cell suspensions from naïve and SIV-infected rhesus macaques were stained for analysis of PD-1 expression. (A) Gating strategy used to identify total CD4þ and CD8þ
T cells as well as CD4þ and CD8þ Tregs. PD-1 expression was evaluated in CD4þ and CD8þ T cells and Tregs in PBMCs (B) and LN (C) cells. (D) PD-1 expression levels were
analyzed in naïve (CD28þCD95), central memory (CM, CD28þCD95þ), and effector memory (EM, CD28CD95þ) CD4þ and CD8þ T cells. PBMC data are pooled from 10
naïve and 12 SIV-infected macaques. LN data are pooled from ﬁve naïve and 12 SIV-infected macaques. Data are shown as means7SEM. npo0.05 and nnpo0.01 indicate
statistically signiﬁcant differences between the compared groups by the Mann–Whitney test.
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B7-DC-Ig in vivo treatment (Mkrtichyan et al., 2012), we separated
dimly (PD-1dim) and highly (PD-1hi) PD-1-expressing T cells and
Tregs in SIV-infected macaques. We initially observed that PD-1
expression in CD4þ T cells and Tregs in SIV-infected macaques was
signiﬁcantly elevated in the PD-1hi subset compared to naïve
macaques, both in PBMCs (Fig. 2B) and LN (Fig. 2C). Similarly,
CD8þ PD-1hi T cells (PBMC and LN) and Tregs (LN only) were also
signiﬁcantly increased (po0.05) in SIV-infected macaques when
compared to naïve animals (data not shown). Notably, PD-1hi
CD4þ T cells and Tregs in the LN of SIV-infected macaques
represented approximately 10–15% of all CD4þ T cells and Tregs,
a signiﬁcant increase when compared to almost undetectable
levels in naïve macaques (po0.01, Fig. 2D).
Impact of ART and ART plus B7-DC-Ig treatment regimens on plasma
and mucosal viral loads
In preliminary pilot studies we determined that B7-DC-Ig given
alone for 4 weeks did not affect plasma viral loads in chronically
SIV-infected macaques (data not shown). Additionally, adminis-
tration of ART in order to ﬁrst decrease viremia in chronically
infected macaques followed by 4 weeks of B7-DC-Ig treatment
alone did not impact viral loads in comparison to controls (data
not shown). Therefore, we decided to study the effect of B7-DC-Ig
treatment given during 11 weeks of ART, and included one group
in which B7-DC-Ig was administered for an extended period of
time following ART cessation. For this purpose, we divided 15
chronically SIV-infected rhesus macaques into three treatment
groups (Groups: A–C, Fig. 3A). The following treatments were
administered to each group: Group A: 11 weeks of daily ART (ART
control group); Group B: 11 weeks of daily ART plus weekly doses
of B7-DC-Ig (ARTþPD-1 modulation group); Group C: 11 weeks of
daily ART plus weekly doses of B7-DC-Ig, followed by an additional
12 weeks of B7-DC-Ig alone (continued PD-1 modulation group).
Fig. 3B–D shows plasma and rectal tissue viral loads for each
animal for the duration of the study. In each group, one animal
failed to signiﬁcantly respond to ART (Fig. 3B–D, underlined codes)
and was therefore not included in further analyses. Geometric
mean plasma viral loads for the remaining four animals per group
are shown in Fig. 4A and display a signiﬁcant response to ART
(490% reduction in plasma and tissue VL) over the 11 weeks
period of treatment in all treatment groups. Although plasma viral
Fig. 2. Proportional distribution of PD-1dim and PD-1hi T cells and Tregs in PBMCs and LN cells of naïve and SIV-infected macaques. (A) PD-1 positive T cells and Tregs display
a bi-modal expression pattern both in PBMCs as well as in lymph nodes. (B)–(D) Freshly isolated PBMC and LN single-cell suspensions from naïve and SIV-infected rhesus
macaques were stained for analysis of PD-1 expression. Percentages of CD4þ PD-1dim and PD-1hi T cells and Tregs in PBMCs (B) and LN (C) cells. (D) Comparative
representation of percentages of PD-1hi CD4þ T cells and Tregs in PBMCs and LN cells. Data are representative (A) or pooled (B)–(D) from at least ﬁve naïve and 12 SIV-
infected macaques. Data are shown as means7SEM. npo0.05, nnpo0.01, and nnnpo0.001 indicate statistically signiﬁcant differences between the compared groups by the
Mann–Whitney test.
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loads were reduced to undetectable levels in only some macaques
(Fig. 3B–D), rectal tissue viral loads were undetectable after
8 weeks of ART in all assayed animals (Figs. 3B–D and 4B).
As expected, upon ART cessation, plasma and rectal tissue viral
loads rebounded in all animals (Fig. 4A and B). Interestingly,
macaques in Group C which remained on B7-DC-Ig for an addi-
tional 12 weeks were signiﬁcantly different from macaques in
Groups A and B (p¼0.03 for the null hypothesis of equal changes
in all three groups). Group C animals showed a decrease in median
plasma viremia after ART release (weeks 13–23) compared to
median pre-ART levels (weeks –11 to 0), whereas Groups A and B
macaques did not (Fig. 4C).
Dynamics of T cell and Treg biodistribution during combined ART
and in vivo PD-1 modulation
Given that during chronic SIV infection the proportional
distribution and function of CD4þ and CD8þ T cells and Tregs
Fig. 3. Therapeutic study design and plasma and rectal tissue viral loads for individual animals throughout the study. (A) Schematic description of the study design
indicating the experimental groups as well as the treatment administered in each group. Time points (in weeks) for sample collection as well as type of samples collected are
indicated. (B)–(D) Plasma and rectal tissue viral loads were obtained at the indicated time points by NASBA. Dotted lines in (B)–(D) indicate the lower limit of viremia
detection (50 copies) by NASBA. Viral loads in Group A (ART-only controls) were previously reported in (Demberg et al., 2012). Animals P149 (Group A), P172 (Group B) and
P798 (Group C) did not respond satisfactorily to ART and were not included in further analyses. #Mamu A*01 positive; %Mamu B*08 positive.
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are altered systemically (Pereira et al., 2007; Fauci and Desrosiers,
1997), and that ART treatment is capable of restoring their normal
proportional distribution (Sellier et al., 2010; Benlhassan-Chahour
et al., 2003), we monitored these cell populations throughout the
duration of the study in PBMCs, LN and rectal tissue. During
the ﬁrst 8 weeks of ART, we observed a signiﬁcant increase in the
proportion of CD4þ T cells (Fig. 5A) in all tissue compartments
assayed. This increase was only transient, and CD4þ T cells started
to decrease proportionally upon ART termination at week 11.
Conversely, CD8þ T cells transiently decreased in proportion
(po0.05, Fig. 5B) in PBMCs and LN during the ﬁrst 8 weeks of
ART. Interestingly, while CD4þ Tregs increased proportionally
during the ﬁrst 8 weeks of ART in LN and rectal tissue, they were
proportionally decreased in PBMCs (po0.05, Fig. 5C). Further-
more, CD8þ Tregs were signiﬁcantly increased during the ﬁrst
8 weeks of ART only in LN (po0.01, Fig. 5D). Overall, neither
combined (during ART, Group B) nor prolonged (during and after
ART, Group C) in vivo PD-1 modulation affected the bio-
distribution of CD4þ and CD8þ T cells and Tregs (Fig. 5A–D).
Effect of B7-DC-Ig on PD-1hi T cells and Tregs
Given that murine B7-DC-Ig affects only cells that express high
amounts of surface PD-1 (Mkrtichyan et al., 2012), and because
high levels of PD-1 expression are observed during the chronic
stage of HIV/SIV infection (Porichis and Kaufmann, 2012), we
monitored the proportion of PD-1hi T cells and Tregs during the
course of this study.
Although ART transiently decreased the percentage of PD-1hi
expressing CD4þ (Fig. 6A) and CD8þ (Fig. 6B) T cells within PBMC,
only animals treated with B7-DC-Ig decreased the percentage of
PD-1hi T cells to levels comparable to those of naïve animals
(Fig. 6A and B dotted line). Moreover, continuous B7-DC-Ig treat-
ment (Group C) maintained PD-1hi T cells at low proportions for up
to 12 weeks post- ART (Fig. 6A and B, week 23). Similarly, PD-1hi
Tregs within PBMC were reduced in Groups B and C that received
B7-DC-Ig but not by ART alone (Fig. 6C and D). Although CD8þ
PD-1hi Tregs were maintained at low levels after ART release
by continuous B7-DC-Ig treatment (Fig. 6D weeks 19 and 23),
CD4þPD-1hi Tregs were maintained at low levels by continuous
B7-DC-Ig treatment for only 2 weeks upon ART release (Fig. 6C).
Similarly to results in PBMC, continuous B7-DC-Ig treatment also
maintained signiﬁcantly lower levels of LN PD-1hiCD4þ and
PD-1hiCD8þ Tregs (Fig. 6G and H), but not T cells (Fig. 6E and F).
Notably, the continuous B7-DC-Ig treatment did not elicit any
toxicity. A previous GLP-compliant pharmacology and toxicology
study in naïve healthy cynomolgus monkeys showed that a 10 mg/
kg weekly repeated dose induced anti-drug antibodies (ADA) in
only a small percentage of animals (data not shown). We did not
assess ADA here, but the extracellular domain of B7-DC is highly
conserved between humans, cynomolgus monkeys and rhesus
macaques (Z96% homology) and we did not expect signiﬁcant
antibody induction that would alter treatment outcomes. This is
supported by the continuous effects of B7-DC-Ig in Group C
macaques on PD-1hi T cells and Tregs in PBMC and LN (Fig. 6A,
B, D, G, and H).
Prolonged B7-DC-Ig treatment transiently modulates Treg phenotype
in SIV-infected macaques and controls the magnitude of Ag-speciﬁc
T-cell responses
Increased PD-1 expression is a reliable marker of immune cell
exhaustion (Day et al., 2006; Shin and Wherry, 2007) and HIV/SIV
viral replication and disease progression (Petrovas et al., 2007).
Increased expression of α4β7 (Kader et al., 2009a,2009b) and Ki67
(Chattopadhyay and Roederer, 2010; Okoye et al., 2007) has also
been associated with HIV/SIV pathogenesis and immune dysfunc-
tion. We monitored α4β7 and Ki67 co-expression in CD4þ and
CD8þ T cells and Tregs during the course of the study. While no
signiﬁcant changes in the levels of α4β7 and Ki67 co-expression
were observed in conventional T cells, α4β7 and Ki67 co-expression
in CD4þ and CD8þ Tregs within PBMC and LN cells were impacted
by continuous B7-DC-Ig treatment (Fig. 7A–D). Within PBMC, con-
tinuous B7-DC-Ig treatment signiﬁcantly decreased CD4þα4β7þ
Ki67þ Tregs 2 weeks post-ART release (Fig. 7A, Group C vs. B, week
13), while a transient (albeit non-signiﬁcant) decrease was observed
at weeks 13 and 19 in CD8þα4β7þKi67þ Tregs (Fig. 7B). In the LN,
ART signiﬁcantly decreased α4β7 and Ki67 co-expression in CD4þ
and CD8þ Tregs of all groups (Fig. 7C and D, week 8). Continuous
B7-DC-Ig treatment (Group C) maintained double-positive α4β7þ
and Ki67þ CD4þ and CD8þ Tregs at signiﬁcantly lower levels for
Fig. 4. Impact of ART and prolonged B7-DC-Ig treatment on viral load rebound.
Geometric mean plasma (A) and mucosal (B) viremia for each group were
determined using the four animals per group that responded satisfactorily to
ART. (C) Pre-ART vs. post-ART median plasma viral load changes in each of the
assayed groups. The changes in pre- vs. post-ART median viral loads were
compared across all three groups by the exact Kruskal–Wallis test.
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Fig. 5. Proportional and compartmental distribution of CD4þ and CD8þ T cells and Tregs over the course of the study. Blood, LN and rectal tissue samples (n¼4 per group)
were collected at different time points as indicated in Fig. 3A and stained for ﬂow cytometric determination of T cell and Treg percentages. Proportional counts of CD4þ
(A) and CD8þ (B) T cells, as well as, CD4þ (C) and CD8þ (D) Tregs were done at each indicated time point for each tissue. Data are shown as means7SEM. npo0.05,
nnpo0.01, and nnnpo0.001 indicate statistically signiﬁcant differences between the indicated time points by the Wilcoxon signed rank test.
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2 weeks post-ART release (Fig. 7C–D, Group C vs. B, week 13). Group
C macaques also exhibited a slower rebound in CD4þ and CD8þ
α4β7þKi67þ Tregs following ART release at week 11. During ART,
both groups exhibited low levels of these cells (Fig. 7C and D, week
8). However the subsequent increase between weeks 8 and 13 in
Group B was signiﬁcantly greater than that of Group C (p¼0.029).
As increased PD-1 expression on T cells during the chronic
phase of HIV/SIV infection leads to T-cell exhaustion (Day et al.,
2006; Wherry 2011; Shin and Wherry, 2007) and because anti-PD-
1 therapy has successfully reversed T-cell exhaustion in cancer and
viral infections (Velu et al., 2009; Macatangay and Rinaldo, 2009;
Rosenblatt et al., 2011; Vezys et al., 2011) we examined SIV-
speciﬁc functional responses of CD4þ and CD8þ T cells over the
course of this study. We evaluated the combined Gag-speciﬁc
production of IFN-γ, IL-2 and TNF-α in total memory (CD95þ
CD287) CD4þ and CD8þ T cells. B7-DC-Ig treatment (Groups B
and C) maintained Gag-speciﬁc cytokine production by total
memory CD8þ T cells at levels lower than those observed pre-
ART for 2 weeks post-ART (Fig. 7E, week 13). Moreover, continued
B7-DC-Ig treatment (Group C) maintained lower Gag-speciﬁc
cytokine responses in total memory CD8þ T cells for 8 weeks
post-ART (Fig. 7E, week 19). Similar albeit not statistically sig-
niﬁcant trends were observed in Gag-speciﬁc cytokine production
by total memory CD4þ T cells under continuous B7-DC-Ig treat-
ment (Fig. 7F, Group C).
Discussion
The potential use of immunomodulatory compounds during anti-
HIV therapy is of great interest as a means to boost Ag-speciﬁc
immune responses and to improve the anti-viral effects of ART and/
or therapeutic vaccination (Zajac et al., 1998; Ha et al., 2008;
Finnefrock et al., 2009). Although ART has been successful at
increasing the life expectancy of HIV-infected individuals, the
severity of ART-related side effects has prompted investigations of
complementary and/or alternative therapeutic approaches that may
lead to use of alternative anti-viral regimens. In this study, we
investigated the immunomodulatory effects of B7-DC-Ig, during and
after ART, in chronically SIV-infected rhesus macaques. We showed
that continuous treatment with B7-DC-Ig caused a moderate overall
decrease for up to 12 weeks in the median rebound viremia after
ART release when compared to median pre-ART levels. Furthermore,
prolonged B7-DC-Ig treatment was associated with a decreased
proportion of PD-1hi expressing CD8þ and CD4þ T cells and Tregs
in PBMCs, and of PD-1hi Tregs in lymph nodes for up to 12 weeks
post-ART. Similarly, prolonged B7-DC-Ig treatment transiently
decreased the expression of Ki67 and α4β7 in PBMC CD4þ and
CD8þ Tregs for up to 8 weeks post-ART and maintained Ag-speciﬁc
T-cell responses at levels lower to those observed pre-ART. Our
results suggest that continuous immune modulation through the
PD-1 pathway using prolonged B7-DC-Ig treatment during and after
ART helps maintain lower systemic VL, keeps a favorable Treg and
T cell repertoire and modulates antigen-speciﬁc responses.
Despite the fact that in vivo PD-1 blockade has previously been
reported to improve Ag-speciﬁc T cell responses during viral
infection (Velu et al., 2009; Nakamoto et al., 2008; Macatangay
and Rinaldo, 2009; Barber et al., 2006; Tzeng et al., 2012; Porichis
et al., 2011), the immunomodulatory potential of a molecule that
selectively targets PD-1hi-expressing cells had not been evaluated
in the context of chronic SIV infection and antiretroviral therapy.
Interestingly, although plasma viral loads decreased similarly
during ART in animals treated with and without B7-DC-Ig, upon
Fig. 6. B7-DC-Ig treatment during and after ART signiﬁcantly decreases the percentage of circulatory PD-1hi CD4þ and CD8þ T cells and Tregs. PBMCs and LN cells were
isolated at the indicated time points and stained for ﬂow cytometric analysis of PD-1 expression. CD4þ (A) and (E) and CD8þ (B) and (F) PD-1hi T cells, as well as, CD4þ
(C) and (G) and CD8þ (D) and (H) PD-1hi Tregs were monitored for the duration of the study in PBMC (A)–(D) and LN (E)–(H). Dotted lines represent mean values of each cell
population obtained from naïve macaques (10 for PBMCs and ﬁve for LN). Data are shown as means7SEM. npo0.05 indicates statistically signiﬁcant differences between
Group A and Group B or C by the Mann–Whitney test. #po0.05 indicates statistically signiﬁcant differences between Group B and Group C by the Mann–Whitney test.
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ART-release, macaques that continued to receive B7-DC-Ig (Group
C) displayed a lower rebound post-ART plasma viral load when
compared to pre-ART values (Fig. 4A and C). Similar, albeit not
statistically signiﬁcant results were observed in rectal tissue viral
loads 2 weeks post-ART (Fig. 4B, week 13). Further, although
frequencies of CD4þ and CD8þ T cells and Tregs ﬂuctuated
similarly across all three treatment groups (Fig. 5), CD4þ and
CD8þ PD-1hi T cells and Tregs within PBMCs maintained the
lowest levels with continued B7-DC-Ig treatment post-ART release
(Group C, Fig. 6). Our results are similar to observations in HBV-
infected patients, where treatment with pegylated interferon led
to long-lasting decreases in the percentage of circulating Tregs and
levels of PD-1 expression in CD4þ and CD8þ T cells in patients
that responded to treatment (Ma et al., 2013). The mechanism
(s) leading to the decreased frequency of PD-1hi T –cells and
Tregs has not been determined, but may include inhibition of
proliferation of PD-1hi CD4 T cells and Tregs as previously reported
(Mkrtichyan et al., 2012). Additionally, preliminary studies
using murine B7-DC-Ig in vitro suggest the possibility of ADCC-
mediated clearance of PD-1 over-expressing cells (Marshall et al.,
unpublished results).
The extent to which the absolute level of viral suppression
during ART affected PD-1hi T cells and Tregs upon ART release
requires further study. Although the magnitude of declines were
similar, plasma viral loads in Groups A and C dropped to lower
levels than that of Group B after 11 weeks of treatment, although
tissue viral loads became undetectable in all three groups (Fig. 4A
and B). In view of the quick viremia rebound in all groups upon
ART release (Fig. 4A), the prolonged maintenance of low level
CD4þ and CD8þ PD-1hi T cells and Tregs in Group C macaques
appears unrelated to viral load rebound (Fig. 6). Similarly, the
slower rebound of Group C macaques in α4β7þKi67þ CD4þ and
CD8þ Tregs in LN over weeks 8–13 also appears unrelated to
absolute viral suppression, as all groups exhibited similar low
levels of these cells during ART (Fig. 7C and D, week 8). Several
factors have been shown to inﬂuence stronger control of HIV
viremia following release of patients from ART, including not only
a low plasma viral load during primary infection, but also a higher
CD4 count and female gender (Goujard et al., 2012). While CD4
counts here were similar among macaque groups at ART initiation
(Fig. 5), two of the four macaques in Group C were females.
Further studies using larger group sizes and extended ART to bring
viral loads to near undetectable levels in all animals will be needed
to conﬁrm these initial results of B7-DC-Ig treatment. (Fig. 5)
Previous studies using anti-PD-1 antibodies have shown pro-
mising results in the treatment of cancerous and viral malignan-
cies (Norde et al., 2012; Velu et al., 2009; Nakamoto et al., 2008;
Sakthivel et al., 2012). These approaches are based on the use of
anti-PD-1 antibodies, which target cells that express PD-1 both at
dim and high levels. Although PD-1 has long been considered a
marker for cell exhaustion, recent evidence shows that in the
context of chronic SIV infection, PD-1 expression by T cells is more
likely to be related to a speciﬁc differentiation or trafﬁcking stage
rather than serving by itself as a reliable marker of immune
exhaustion (Hong et al., 2013). Given that our B7-DC-Ig-
mediated treatment uniquely targets PD-1hi expressing cells with-
out blocking PD-1-mediated signaling (Mkrtichyan et al., 2012),
our therapy targets mostly exhausted PD-1hi-expressing cells, and
does not eliminate all PD-1-expressing T cell subpopulations.
Despite this selective targeting of exhausted PD-1hi-expressing
Fig. 7. Prolonged B7-DC-Ig treatment transiently decreases Ki67 and α4β7 expression in Tregs and maintains Ag-speciﬁc CD8þ T-cell responses at levels lower than those
observed before ART. (A)–(D) PBMC and LN samples were isolated at the indicated time points and stained for ﬂow cytometric analysis of Ki67 and α4β7 expression on CD4þ
and CD8þ Treg cells. Co-expression of Ki67 and α4β7 on CD4þ (A) and CD8þ (B) Tregs within PBMCs. (C) and (D) Co-expression of Ki67 and α4β7 on CD4þ (C) and CD8þ
(D) Tregs within LN cells. Dotted lines represent mean values of Ki67þα4β7þ CD4þ and CD8þ Tregs as calculated from naïve macaques (10 for PBMCs and ﬁve for LN).
(E) and (F) Combined Gag-speciﬁc cytokine responses (IFN-γ/TNF-α/IL-2) in total memory (CD28þCD95/þ) CD8þ (E) and CD4þ (F) T cells. Data are shown as means7SEM.
In (C) and (D), ∧∧∧po0.001 indicates statistically signiﬁcant differences between the indicated time points by the Wilcoxon signed rank test. npo0.05 indicates statistically
signiﬁcant differences between Group A and Group B or C by the Mann–Whitney Test. #po0.05 indicates statistically signiﬁcant differences between Group B and Group C
by the Mann–Whitney test.
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T cells and Tregs, we did not see an improvement of antigen-speciﬁc
responses by CD4þ and CD8þ T cells and thus further experiments
are needed to directly compare both anti-PD-1 immunomodulation
approaches (PD-1 blockade and B7-CD-Ig treatment) in anti-cancer
and anti-viral models.
We speculate that the lower levels of exhausted cells in Group
C led to improved functional activities, resulting in a slower rate of
viral rebound. A decrease in dysfunctional PD-1hi Tregs could have
favored better Treg functionality and better control of immune
activation, therefore reducing the number of targets for SIV
infection. Additionally, the decrease in PD-1hi T cells in the PBMC
compartment could have provided sustained immune control of
viremia following the initial reductions attributable to ART. More-
over, although the ART/B7-DC-Ig-mediated decrease of CD4þ
PD-1hi T cells in the LN compartment was not signiﬁcant
(Fig. 4E), follicular helper CD4þPD-1hi T cells (Tfh) have been
recently shown to accumulate in LN and serve as SIV reservoirs
during chronic infection (Klatt et al., 2011; Perreau et al., 2013;
Hong et al., 2012). Thus, a B7-DC-Ig-mediated decrease in Tfh
abundance may have contributed to the lower rebound in plasma
VL observed. As the current study did not include phenotypic
markers for Tfh cells, future studies need to further assess the
impact of B7-DC-Ig on these cells. Furthermore, the SIV-mediated
accumulation of PD-1hi T cells in the LN (Fig. 2D) may reﬂect the
need of a higher B7-DC-Ig dose for signiﬁcantly reducing PD-1hi T
cells at this location.
Given that α4β7 blockade has previously been shown to reduce
plasma and tissue viral loads in SIV-infected macaques (Ansari
et al., 2011), we hypothesize that the reductions in plasma viral
loads observed in our study might also be due to the B7-DC-Ig-
induced transient decrease of α4β7þ and Ki67þ CD4þ Tregs
observed in PBMCs and LN (Fig. 7A and C). As Foxp3 (Suchard
et al., 2010) and CD25 are markers of T cell activation, and α4β7hi
memory CD4þ T cells are preferentially infected by SIV (Kader
et al., 2009), the overall reduction of α4β7- and Ki67-expressing
CD4þCD25þFoxp3 cells might also reﬂect an overall decrease in
SIV target cell availability and therefore explain the reduction in
plasma viral loads observed in Group C.
We initially observed that in SIV-infected rhesus macaques, the
highest level of PD-1 expression (PD-1hi cells) was exhibited by
CD4þ Treg and T cells residing in the LN (Fig. 2D). Given that
ARTþB7-DC-Ig treatment signiﬁcantly reduced the percentages of
PD-1hi CD4þ and CD8þ T cells and Tregs within PBMCs (Fig. 6), we
expected an overall increase in the responding capacity of
CD4þ and CD8þ T cells in Ag-speciﬁc recall assays. However, as
mentioned above, CD4þ and CD8þ T cell Ag-speciﬁc immune
responses ﬂuctuated during ART and ARTþB7-DC-Ig treatment
but were maintained at levels lower than those at the start of
treatment by continuous administration of B7-DC-Ig (Fig. 7E and F).
Although B7-DC-Ig treatment selectively depletes “exhausted” PD-
1hi cells, the reduction in SIV antigenic load caused by ART
presumably led to the decline observed in Ag-speciﬁc immune
responses. In this regard, it has previously been reported that HIV-
infected individuals receiving ART have a decrease in the magnitude
and diversity of their virus-speciﬁc T cell receptor repertoire
(Conrad et al., 2012). Furthermore, initiation of ART has also been
correlated with a decrease in the levels of HIV-speciﬁc cytotoxic
responses of effector and memory CD8þ T cells (Casazza et al.,
2001; Kalams et al., 1999).
As summarized in recent reviews, the impact of Treg cells on
HIV infection and disease progression is not clear (Moreno-
Fernandez et al., 2012; Chevalier and Weiss, 2013). Treg cells
may be detrimental, as they suppress viral-speciﬁc immune
responses. On the other hand, Treg cells can control immune
activation, thereby decreasing overall pathology as well as the
number of target cells available for HIV infection. The Treg
dichotomy may be best exhibited during the different phases of
disease progression. As hypothesized by Holmes et al. (2008), prior
to or during acute HIV infection, Treg cells may decrease viral-
speciﬁc immunity while increasing the number of available target
cells. In contrast, during the chronic phase of infection, Tregs may
reduce immune activation, thereby reducing viremia and slowing
T cell loss. Here, in macaques studied during the chronic phase of
infection, we observed no differences in Treg cells among groups
over the course of the study. However, macaques treated with
continuous B7-DC-Ig exhibited prolonged maintenance of a lower
level of PD-1hi Tregs. Loss of these dysfunctional, exhausted cells
could have provided enhanced function relative to the other
groups of macaques, leading to better control of immune activa-
tion and better control of rebound viremia as we observed. Our
results thus support the hypothesis of Holmes et al. (2008). We
expect that the treatment with ART earlier in the disease course
together with prolonged treatment with the B7-DC-Ig immune
modulator might have more profound effects on viremia outcome
and allows better discrimination of effects on immune response
and disease progression.
Materials and methods
Animals and sample collection
Fourteen naive and 23 SIVmac251-positive rhesus macaques,
chronically infected for 23–65 weeks, were housed at Advanced
BioScience Laboratories, Inc. (ABL; Kensington, MD) or the NIH
Animal Center (Poolesville, MD). Animals were maintained accord-
ing to Institutional Animal Care and Use Committee guidelines and
the NIH Guide for the Care and Use of Laboratory Animals. Fifteen
of the SIV-infected macaques, recycled from previous vaccine
studies (Pegu et al., 2012; Xiao et al., 2012) were divided into
three treatment groups (Fig. 2A) based on their previous immu-
nization status, VL and CD4þ T-cell counts. Two macaques in
Groups A and B and one in Group C were Mamu An01 positive;
Group C also contained one Bn08 positive macaque (Fig. 3B–D).
ART composition and dosages were previously described
(Demberg et al., 2012). B7-DC-Ig fusion protein (Amplimmune,
Inc.; Gaithersburg, MD) was administered intravenously weekly at
10 mg/kg. B7-DC-Ig binding to macaque CD3þ T cells was con-
ﬁrmed by direct staining of PBMC with APC-conjugated B7-DC-Ig
(data not shown).
Blood samples were collected by venipuncture of anesthetized
animals into EDTA-treated collection tubes. Peripheral blood
mononuclear cells (PBMC) were obtained using Ficoll–Paque PLUS
gradients (GE Healthcare; Piscataway, NJ). Cells were washed and
resuspended at 1106 cells/mL in R-10 medium (RPMI 1640
containing 10% FBS, 2 mM L-glutamine, 1% non-essential amino
acids, 1% sodium pyruvate and antibiotics). Lymph node (LN)
biopsies were minced, passed through a 40 μm cell strainer, and
lysed to remove red blood cells. Rectal biopsies were digested for
60 min on an orbital shaker in R-10 medium containing 1 mg/mL
of collagenase II (Sigma; St Louis, MO). VL in plasma and rectal
tissue were determined by NASBA (Lee et al., 2010).
Flow cytometry
Anti-human ﬂuorochrome-conjugated monoclonal antibodies
(mAbs) known to cross-react with rhesus macaques and used in
the present study are described in Table 1. Yellow and aqua LIVE/
DEAD viability dyes (Invitrogen; Grand Island, NY) were used to
exclude dead cells. For multiparametric ﬂow cytometry analysis,
PBMCs and tissue mononuclear cells were stained for speciﬁc
surface molecules, ﬁxed and permeabilized with either the
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Transcription Factor Staining Buffer Set (eBioscience; San Diego,
CA) or with the Cytoﬁx/Cytoperm Kit (BD Biosciences; San Jose,
CA), and then stained for speciﬁc intracellular molecules. At least
500,000 singlet events (PBMCs) or 30,000 CD3þ singlet events
(tissue mononuclear cells) were acquired on a 4-laser LSR II SORP
(BD Biosciences) and analyzed using the FlowJo Software (TreeStar
Inc; Ashland, OR). For all samples, gating was established using a
combination of isotype and ﬂuorescence-minus-one controls.
Given that PD-1hi cells are enriched in the LN of SIV-infected
macaques, we used LN cells to set up the ﬂow cytometry gates that
differentiate PD-1 negative, dim and high expression levels.
T cell recall assays
T cell recall responses were assayed by stimulating 2106
PBMCs with 1 μg/mL SIVmac239 Gag peptide pools (complete sets of
15-mer peptides, overlapping by 11 and spanning the entire
protein; NIH AIDS Research & Reference Reagent Program) for
6 h. Stimulation was performed in the presence of 10 μg/mL
Brefeldin A, 2 μg/mL anti-CD49d and 0.375 μg/mL PE-Cy7 anti-
CD28 (all from BD Biosciences). CD3þ T cells were divided into
CD4þ and CD8þ populations and for each, cells were further
subdivided into CD28þCD95þ central (CM) and CD28CD95þ
effector memory (EM) cells. Percent cytokine secreting cells
among each memory subset were then determined. Non-
stimulated and SEB-treated (5 μg/mL; Sigma) tubes were used as
negative and positive controls, respectively. Non-stimulated values
were subtracted from Gag-stimulated samples to calculate Gag-
speciﬁc cytokine secreting cells.
Statistical analysis
Unless otherwise speciﬁed, all data reported were averaged
from the number of macaques indicated in the ﬁgure legends.
Results are shown as means7standard errors of the mean. Data
were analyzed using Prism (v5.03, GraphPad Software). A p value
of r0.05 was considered statistically signiﬁcant for each test.
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